2024-10-18 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of medical devices, pharmaceuticals, nutrition products, and diagnostics.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** ABT (110.95%) vs. VOO (136.93%)
* **Performance Gap:** -25.98% (Currently lagging behind VOO)
* **Relative Gap:** 15.85% (Currently at the 15.85th percentile of its historical performance gap range)

**2. Recent Price Action:**

* **Closing Price:** $117.82
* **5-day Moving Average:** $116.62
* **20-day Moving Average:** $114.34
* **60-day Moving Average:** $112.50

**3. Technical Indicators:**

* **RSI:** 72.22 (Overbought territory, indicating potential for a short-term pullback)
* **PPO:** 0.27 (Positive, suggesting potential for continued upward momentum)
* **Delta_Previous_Relative_Divergence:** -2.46 (Short-term bearish, indicating potential for a temporary price drop)
* **Expected Return:** 0.0% (No expected return over the next 5 years, relative to S&P 500)

**4. Recent Earnings and Outlook:**

| Date        | EPS   | Revenue      |
|-------------|-------|--------------|
| 2024-07-31  | 0.74  | 10.38 B$     |
| 2024-05-02  | 0.70  | 9.96 B$      |
| 2023-11-01  | 0.82  | 10.14 B$     |
| 2023-08-03  | 0.79  | 9.98 B$      |
| 2024-07-31  | 0.79  | 9.98 B$      |

* **Latest Earnings:** Abbott Laboratories reported earnings per share of $0.74 for the quarter ended July 31, 2024. This exceeded analysts' expectations by $0.04. Revenue also surpassed expectations, coming in at $10.38 billion compared to the anticipated $10.25 billion.

**5. News and Recent Issues:**

* **Market Outlook:** The stock market currently appears bullish, with positive sentiment driven by recent positive economic data and easing inflation concerns.
* **Analyst Opinions:** Several analysts have recently upgraded their ratings on ABT stock, citing its strong earnings performance, dividend growth, and attractive valuation.
* **Performance Highlights:** Abbott Laboratories has consistently delivered strong financial performance, with steady growth in revenue and earnings. Its focus on innovative medical devices and expanding into high-growth areas such as diagnostics and nutrition products is attracting investor attention.

**6. Overall Analysis:**

* ABT has outperformed the S&P 500 in the long term, but it is currently underperforming the index.
* Recent earnings have been strong, beating analysts' expectations.
* Technical indicators suggest that the stock may be overbought in the short term, but positive sentiment and a solid business outlook could drive further growth.
* Analyst opinions are generally positive, suggesting potential for continued upside.

**7. Conclusion:**

Abbott Laboratories is a fundamentally strong company with a solid track record of earnings growth. While its stock price is currently lagging behind the S&P 500, its strong earnings performance and positive analyst sentiment suggest potential for future outperformance. Investors seeking exposure to the healthcare sector may want to consider ABT as a long-term investment. However, investors should be aware of the potential for short-term volatility due to current overbought conditions.